# Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

> **NCT00752973** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Pediculosis

## Interventions

- **DRUG:** MALG (malathion) Treatment

## Key facts

- **NCT ID:** NCT00752973
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752973, "Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00752973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*